Plasminogen activator inhibitor-1 is an independent prognostic factor of ovarian cancer and IMD-4482, a novel plasminogen activator inhibitor-1 inhibitor, inhibits ovarian cancer peritoneal dissemination

In the present study, the therapeutic potential of targeting plasminogen activator inhibitor-1 (PAI-1) in ovarian cancer was tested. Tissues samples from 154 cases of ovarian carcinoma were immunostained with anti-PAI-1 antibody, and the prognostic value was analyzed. Among the samples, 67% (104/154...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakatsuka, Erika, Sawada, Kenjiro, Nakamura, Koji, Yoshimura, Akihito, Kinose, Yasuto, Kodama, Michiko, Hashimoto, Kae, Mabuchi, Seiji, Makino, Hiroshi, Morii, Eiichi, Yamaguchi, Yoichi, Yanase, Takeshi, Itai, Akiko, Morishige, Ken-ichirou, Kimura, Tadashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685717/
https://www.ncbi.nlm.nih.gov/pubmed/29163796
http://dx.doi.org/10.18632/oncotarget.20834

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685717/
https://www.ncbi.nlm.nih.gov/pubmed/29163796
http://dx.doi.org/10.18632/oncotarget.20834

Ejemplares similares